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Review criteriaEmbase^™^, MEDLINE^®^, MEDLINE^®^ In‐Process, and The Cochrane Library were searched on two occasions using relevant MeSH terms combined with free‐text terms. References were screened by two independent reviewers. Relevant publications were then extracted by two independent reviewers, with a third reviewer collating and finalising extractions.Message for the clinicThere is a lack of high‐quality clinical evidence supporting the therapeutic use of demeclocycline for HN secondary to SIADH. The safety profile of demeclocycline is variable with an inconsistent time to onset, and a potential for complications. Economic evaluations or HRQoL studies of demeclocycline for the treatment of HN secondary to SIADH have not been performed. Patients receiving demeclocycline must be closely monitored.

Introduction {#ijcp12713-sec-0009}
============

Hyponatraemia (HN), defined as a serum sodium concentration \< 135 mmol/l, is the most common metabolic disorder of body water and total body sodium concentration. HN is usually associated with a disturbance in vasopressin \[antidiuretic hormone (ADH)\], which can be synthesised independently of serum osmolality or circulating fluid volume under specific pathological or pharmacological conditions [1](#ijcp12713-bib-0001){ref-type="ref"}. Clinical criteria for the syndrome of inappropriate antidiuretic hormone secretion (SIADH) were established by Bartter and Schwartz [2](#ijcp12713-bib-0002){ref-type="ref"} and have remained largely unchanged ever since [1](#ijcp12713-bib-0001){ref-type="ref"}. SIADH accounts for one‐third of all cases of HN [3](#ijcp12713-bib-0003){ref-type="ref"}.

Hyponatraemia occurs in approximately 30% of hospitalised patients [1](#ijcp12713-bib-0001){ref-type="ref"}, [4](#ijcp12713-bib-0004){ref-type="ref"} and is a clinical feature in 15--20% of emergency admissions [1](#ijcp12713-bib-0001){ref-type="ref"}. HN has a wide range of aetiologies across several patient populations. In the great majority of patients, its aetiology is multifactorial [5](#ijcp12713-bib-0005){ref-type="ref"}. HN secondary to SIADH is associated with significant morbidity [6](#ijcp12713-bib-0006){ref-type="ref"}, mortality [7](#ijcp12713-bib-0007){ref-type="ref"}, [8](#ijcp12713-bib-0008){ref-type="ref"}, [9](#ijcp12713-bib-0009){ref-type="ref"}, [10](#ijcp12713-bib-0010){ref-type="ref"} and increased length of hospital stay [11](#ijcp12713-bib-0011){ref-type="ref"}. Symptoms are associated primarily with the severity of the HN, and range from confusion and vomiting in mild HN (\< 135 mmol/l sodium) to seizures, coma and death in severe cases (\< 125 mmol/l sodium; Figure [1](#ijcp12713-fig-0001){ref-type="fig"}) [4](#ijcp12713-bib-0004){ref-type="ref"}, [12](#ijcp12713-bib-0012){ref-type="ref"}, [13](#ijcp12713-bib-0013){ref-type="ref"}. In addition to symptoms, patients are subject to serious sequelae of HN, including gait abnormalities, falls [14](#ijcp12713-bib-0014){ref-type="ref"}, and an increased fracture risk [15](#ijcp12713-bib-0015){ref-type="ref"}. Such morbidities are clinically significant, as HN is particularly common in elderly people [12](#ijcp12713-bib-0012){ref-type="ref"}.

![Morbidity and symptoms associated with hyponatraemia [4](#ijcp12713-bib-0004){ref-type="ref"}, [13](#ijcp12713-bib-0013){ref-type="ref"}](IJCP-69-1396-g001){#ijcp12713-fig-0001}

There is a substantial economic healthcare burden associated with HN, which include significant increases in length of hospital stay, hospital costs and intensive care unit (ICU) costs, as well as an increase in the risk of ICU admission and 30‐day hospital readmission. Studies in the USA estimate that direct costs for treating HN range from \$1.6 to \$3.6 billion annually [16](#ijcp12713-bib-0016){ref-type="ref"}.

Current management strategies for acute symptomatic HN secondary to SIADH comprise hypertonic (3%) saline given either via bolus or continuous intravenous infusion, with or without diuretics. Patients with euvolaemic hypo‐osmolality because of SIADH do not respond to isotonic saline, and occasionally, this causes HN to worsen [16](#ijcp12713-bib-0016){ref-type="ref"}. In chronic HN (\< 135 mmol/l for \> 48 h) secondary to SIADH, fluid restriction is considered first‐line treatment in patients without severe symptoms or where hypovolaemia is not suspected [1](#ijcp12713-bib-0001){ref-type="ref"}, [16](#ijcp12713-bib-0016){ref-type="ref"}. Fluid restriction between 500 and 1000 ml/day is recommended, according to HN severity [17](#ijcp12713-bib-0017){ref-type="ref"}. Pharmacological therapy generally comprises a vaptan (specific vasopressin‐2 receptor antagonists) or demeclocycline in some countries (e.g. France and the UK); other options may include urea or loop diuretics or combinations of above treatments [16](#ijcp12713-bib-0016){ref-type="ref"}.

The aim of HN management was to normalise the serum sodium concentration whilst avoiding the risk of osmotic demyelination syndrome (ODS; previously known as central pontine myelinolysis). It is important to limit the correction of sodium to a maximum rate of 12 mmol/24 h, and to this end, it is important that patients are in an environment suitable for monitoring with regular estimations of sodium levels. If HN is known to be of short duration (\< 48 h), correction may be carried out at a faster rate as the risk of cerebral oedema in a patient with severely symptomatic HN outweigh the risks of ODS. It should also be remembered that often, the aim was to restore the sodium to a 'safe' level rather than achieve sodium normalisation. Most physicians suggest regular review of sodium levels and less invasive action once sodium levels reach 120--125 mmol/l [16](#ijcp12713-bib-0016){ref-type="ref"}.

Demeclocycline is a tetracycline derivative antibiotic, with a marketing authorisation in the UK for the treatment of chronic HN associated with SIADH secondary to malignant disease, where water restriction is ineffective and the patient does not have concomitant cirrhosis [18](#ijcp12713-bib-0018){ref-type="ref"}. In France, demeclocycline is reimbursed for the treatment of SIADH, particularly with an origin of paraneoplastic syndrome with chronic hyponatraemia (\< 125 mmol/l) associated with inappropriate natriuresis, and/or clinical signs associated with hyponatraemia resistant to fluid restriction [19](#ijcp12713-bib-0019){ref-type="ref"}. Although its mode of action has not yet been established, it is thought that demeclocycline induces nephrogenic diabetes insipidus in approximately 60% of patients with HN secondary to SIADH, resulting in decreased urine concentration and rebalancing of body sodium concentrations [12](#ijcp12713-bib-0012){ref-type="ref"}, [16](#ijcp12713-bib-0016){ref-type="ref"}. Onset of action is unpredictable, usually occurring after 2--5 days, but occasionally taking longer [3](#ijcp12713-bib-0003){ref-type="ref"}, [12](#ijcp12713-bib-0012){ref-type="ref"}, [16](#ijcp12713-bib-0016){ref-type="ref"}.

Treatment with demeclocycline has been associated with gastrointestinal intolerance, including nausea and vomiting, nephrotoxicity and renal failure [18](#ijcp12713-bib-0018){ref-type="ref"}; cases of reversible renal failure have also been reported [20](#ijcp12713-bib-0020){ref-type="ref"}, [21](#ijcp12713-bib-0021){ref-type="ref"}, [22](#ijcp12713-bib-0022){ref-type="ref"}. As with all antibiotics, overgrowth of resistant organisms may cause candidiasis [18](#ijcp12713-bib-0018){ref-type="ref"}.

To our knowledge, there has been no systematic evaluation of the use of demeclocycline for the treatment of HN secondary to SIADH to date, and its use appears to be supported by subjective familiarity rather than objective evidence. Therefore, a systematic literature review of all available evidence was performed to obtain an insight into the clinical safety and efficacy of demeclocycline for this condition. To further understand the financial impact of treating with demeclocycline, an economic component was included within the search criteria.

Methods {#ijcp12713-sec-0010}
=======

A comprehensive search strategy was employed following Preferred Reporting Items for Systematic reviews and Meta‐Analyses (PRISMA) standards [23](#ijcp12713-bib-0023){ref-type="ref"}. Embase^™^, MEDLINE^®^, MEDLINE^®^ In‐Process, and The Cochrane Library were searched using Medical Subject Heading (MeSH) terms, combined with free‐text terms (see Appendix [A](#ijcp12713-app-0001){ref-type="app"} for full search strings). Disease search terms comprised terminological variations of SIADH, HN and key clinical indicators (e.g. sodium serum and urine osmolality). References were then limited to those relating to demeclocycline, and considered relevant if primary data sources examined the use of demeclocycline in patients with HN because of SIADH.

Inclusion criteria for the search output were limited to any study examining the clinical efficacy or long‐term/real‐world effectiveness of demeclocycline, case reports with more than five patients where only clinical efficacy (rather than safety) was reported, or case reports with one or more patients reporting any safety outcomes. In addition, studies presenting cost‐effectiveness or health‐related quality of life (HRQoL) data for demeclocycline in the treatment of HN associated with SIADH were also included.

Potentially relevant references identified from the search output were screened electronically by two independent reviewers and any differences subsequently adjudicated by a third reviewer. Full publications of the resulting, potentially relevant studies were then reviewed before the included study list was finalised. Relevant publications were extracted into a predesigned data extraction table by two independent reviewers, with a third reviewer collating and finalising the extractions. Papers published in languages other than English or French were included only if sufficient data were available in English‐language abstracts. Quality assessment was conducted for randomised controlled trials (RCTs) and cohort studies using the 2011 Scottish Intercollegiate Guidelines Network checklists ([www.sign.ac.uk](http://www.sign.ac.uk)).

The comprehensive literature search was performed on 28 May 2014. Subsequently, a second search was undertaken to identify relevant studies published between March and December 2014; searches occurred on the 9 December 2014 and were performed to an identical protocol.

Results {#ijcp12713-sec-0011}
=======

Search outputs {#ijcp12713-sec-0012}
--------------

Searches outputs from the initial protocol (28 May 2014) returned 679 hits. After the electronic removal of 71 duplicate references, 608 abstracts were screened. Upon completion of dual electronic screening, the full‐length publications of 25 studies were ordered for full review; five further studies were available as conference abstracts only. Of these, 12 were excluded (Appendix [B](#ijcp12713-app-0002){ref-type="app"} summarises the excluded papers), resulting in 18 studies deemed relevant for data extraction.

Results from the second, updated literature search (March to December 2014) produced 26 hits. After the removal of two duplicate references, 24 abstracts were screened; five studies were identified for full review following electronic screening. Of these, all abstracts were excluded (Appendix [B](#ijcp12713-app-0002){ref-type="app"}), resulting in no additional studies deemed relevant for data extraction (Figure [2](#ijcp12713-fig-0002){ref-type="fig"}).

![Combined PRISMA flow diagram for the original systematic review and update, showing the total combined publications detected in the original and updated literature searches. As there was a 3‐month overlap between search dates, some publications may be detected twice. An adjustment for this possibility was not made. RCT, randomised controlled trial](IJCP-69-1396-g002){#ijcp12713-fig-0002}

Systematic review {#ijcp12713-sec-0013}
-----------------

Of the 18 studies deemed relevant for data extraction, two RCTs were identified (Table [1](#ijcp12713-tbl-0001){ref-type="table-wrap"}) [24](#ijcp12713-bib-0024){ref-type="ref"}. Alexander et al. compared demeclocycline with placebo in nine patients with chronic psychiatric illness and episodic or chronic HN (\< 135 mmol/l) associated with polydipsia [24](#ijcp12713-bib-0024){ref-type="ref"}; Horattas et al. compared demeclocycline with placebo in 30 patients undergoing elective coronary artery bypass grafting (CABG) [25](#ijcp12713-bib-0025){ref-type="ref"}.

###### 

Included randomised controlled trials -- study design

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author, year \[study name\]                                       Patient population                                                                                                     Study design                                                    Eligibility criteria                                                                                                                    Interventions                                                                                                     Study outcomes                                                                                                                                                      Demeclocycline dose
  ----------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------
  Alexander et al. 1991 [24](#ijcp12713-bib-0024){ref-type="ref"}   Nine psychiatric patients (six male), aged 31--47 years (mean, 38.3 years), with polydipsia‐HN                         Randomised, double‐blind, placebo‐controlled cross‐over trial   Chronic psychiatric illness and documented episodic or chronic HN (\< 135 mmol/l) associated with polydipsia                            Demeclocycline or placebo\                                                                                        Body weight; serum sodium levels; number of episodes of sodium levels \<125 or \< 135 mmol/l                                                                        300 mg for 3 weeks (twice daily for 7 days; three times daily for 7 days; four time daily for 7 days)
                                                                                                                                                                                                                                                                                                                                                                                                   Stable daily doses of neuroleptics                                                                                                                                                                                                                                                    

  Horattas et al. 1998 [25](#ijcp12713-bib-0025){ref-type="ref"}    Thirty patients (20 male), aged 40--70 years (mean, 61.4 years), undergoing elective coronary artery bypass grafting   Randomised, double‐blind, placebo‐controlled clinical study     Normal electrolytes and renal function\                                                                                                 600 mg DMC or placebo twice daily, beginning 5 days pre‐operatively and continuing through postoperative day 2\   Serum electrolytes; complete blood counts; prothrombin time; partial thromboplastin time; arterial blood gases; urine electrolytes; osmolality; serum vasopressin   600 mg (twice daily) from day 5 pre‐operation to day 2 post operation
                                                                                                                                                                                                                                                           Exclusions: renal or hepatic dysfunction; endocrine abnormalities; pregnancy; recent antibiotic use; hypersensitivity to tetracycline   Pain medication and/or antihypertensives                                                                                                                                                                                                                                              
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

DMC, demeclocycline; HN, hyponatraemia.

John Wiley & Sons, Ltd

In total, 16 non‐RCTs were considered relevant, comprising six cohort studies (four observational studies [20](#ijcp12713-bib-0020){ref-type="ref"}, [22](#ijcp12713-bib-0022){ref-type="ref"}, [26](#ijcp12713-bib-0026){ref-type="ref"}, [27](#ijcp12713-bib-0027){ref-type="ref"}, two retrospective chart analyses [21](#ijcp12713-bib-0021){ref-type="ref"}, [28](#ijcp12713-bib-0028){ref-type="ref"}, and 10 case reports [29](#ijcp12713-bib-0029){ref-type="ref"}, [30](#ijcp12713-bib-0030){ref-type="ref"}, [31](#ijcp12713-bib-0031){ref-type="ref"}, [32](#ijcp12713-bib-0032){ref-type="ref"}, [33](#ijcp12713-bib-0033){ref-type="ref"}, [34](#ijcp12713-bib-0034){ref-type="ref"}, [35](#ijcp12713-bib-0035){ref-type="ref"}, [36](#ijcp12713-bib-0036){ref-type="ref"}, [37](#ijcp12713-bib-0037){ref-type="ref"}, [38](#ijcp12713-bib-0038){ref-type="ref"} (Tables [2](#ijcp12713-tbl-0002){ref-type="table-wrap"} and [3](#ijcp12713-tbl-0003){ref-type="table-wrap"}, respectively); no cost‐effectiveness or HRQoL studies were identified. Quality assessments for all studies other than case reports are presented (Appendix [C](#ijcp12713-app-0003){ref-type="app"}).

###### 

Included cohort studies -- study design

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author, year                                                            Patient population                                                                       Study design                              Eligibility criteria                                                                                                    Interventions                                                                   Study outcomes                                                                                                      Demeclocycline dose
  ----------------------------------------------------------------------- ---------------------------------------------------------------------------------------- ----------------------------------------- ----------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------
  De Troyer et al. 1977 [20](#ijcp12713-bib-0020){ref-type="ref"}         Seven male patients with lung carcinoma, aged 48--76 years                               Observational study                       SIADH                                                                                                                   DMC                                                                             Serum sodium; urine osmolality; blood urea, creatinine; water clearance                                             300 mg DMC four times daily, reduced to 600 mg/day after 10 days.

  Forrest et al. 1978 [26](#ijcp12713-bib-0026){ref-type="ref"}           Ten patients (eight male) with chronic SIADH, aged 6--68 years                           Observational study                       HN despite fluid restriction; SIADH                                                                                     DMC\                                                                            Serum sodium; urine osmolality; urinary sodium excretion                                                            600--1200 mg DMC daily given to 10 patients.
                                                                                                                                                                                                                                                                                                                                     Three patients given lithium prior to DMC.                                                                                                                                                          

  Goldman and Luchins, 1985 [27](#ijcp12713-bib-0027){ref-type="ref"}     Eight psychiatric patients (seven male), aged 43--54 years, with polydipsia‐HN           Observational study                       Compulsive water drinkers; hyponatraemic (115--130 mmol/l); not taking carbamazepine                                    DMC\                                                                            Serum sodium; urine osmolality                                                                                      600 mg (twice daily) for 3 weeks
                                                                                                                                                                                                                                                                                                                                     Stable daily doses of neuroleptics                                                                                                                                                                  

  Perks et al. 1979 [22](#ijcp12713-bib-0022){ref-type="ref"}             Fourteen patients (seven male); mean age of 61 years.                                    Observational study                       Diagnosis of SIADH based on De Troyer and Demanet (1976) criteria [37](#ijcp12713-bib-0037){ref-type="ref"}             DMC                                                                             Serum electrolytes, urea, creatinine, osmolarity and packed cell volume                                             1200 mg/day

  Brewerton and Jackson, 1994 [28](#ijcp12713-bib-0028){ref-type="ref"}   Six psychiatric patients (one male), aged 37--80 years (mean 56.0 years)                 Retrospective chart analysis              Patients taking carbamazepine who were forced to discontinue because of HN not associated with psychogenic polydipsia   DMC\                                                                            Mean serum sodium                                                                                                   300 mg (twice daily), increased to 600 mg (twice daily) by day 3--5\
                                                                                                                                                                                                                                                                                                                                     Carbamazepine was administered concomitantly or initiated 3--7 days after DMC                                                                                                                       Average duration of treatment was 11.3 days

  Trump, 1981 [21](#ijcp12713-bib-0021){ref-type="ref"}                   Patients with malignancies who received DMC for4 or more days forserious HN (*n* = 15)   Retrospective review of patient records   Serious HN (\< 125 mmol/l); no oedema or dehydration; normal serum creatinine and urea nitrogen                         DMC\                                                                            Serum sodium, osmolality, urea nitrogen; urine sodium, osmolality; average daily intake/output; bilirubin, weight   600--1200 mg/day
                                                                                                                                                                                                                                                                                                                                     Seven patients were additionally receiving corticosteroids                                                                                                                                          
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

DMC, demeclocycline; HN, hyponatraemia; SIADH, symptom of inappropriate antidiuretic hormone secretion.

John Wiley & Sons, Ltd

###### 

Relevant case reports -- study summary

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author, year                                                                                  Patient population                                                                                                    Interventions                                                          Outcome                                                                                                                                                                                Author conclusion
  --------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------
  Antonelli et al. 1993 [29](#ijcp12713-bib-0029){ref-type="ref"}                               A 59‐year‐old man\                                                                                                    300 mg DMC twice daily for about 3 weeks\                              Patient developed phosphate diabetes after 4 days of DMC\                                                                                                                              Phosphate diabetes may be related to selective DMC‐induced tubulopathy
                                                                                                Slight fever, dyspnoea, weight loss, asthenia and mental slowness                                                     Water restriction\                                                     Progressive amelioration of the symptomatology and resolution of SIADH after DMC discontinuation and the start of corticosteroids                                                      
                                                                                                                                                                                                                      Hypertonic saline iv\                                                                                                                                                                                                                                         
                                                                                                                                                                                                                      Corticosteroid treatment for 10 months                                                                                                                                                                                                                        

  Curtis et al. 2002 [30](#ijcp12713-bib-0030){ref-type="ref"}                                  A 94‐year‐old man hospitalised following collapse\                                                                    300 mg DMC three times daily plus fluid restriction\                   Fatal acute renal failure                                                                                                                                                              Short‐term DMC can effectively control symptomatic HN but caution is required because of its potential nephrotoxicity\
                                                                                                Diagnosis of SIADH                                                                                                    Nine days after admission, DMC increased to four times daily\                                                                                                                                                                                                 Authors note a danger of dehydration in patients whose fluid intake has become compromised\
                                                                                                                                                                                                                      Metronizadole\                                                                                                                                                                                                                                                Authors suggest that had DMC been discontinued once the HN had resolved, the development of acute renal failure would have been avoided
                                                                                                                                                                                                                      Benzydamine hydrochloride mouth washes                                                                                                                                                                                                                        

  Danovitch et al. 1978 [31](#ijcp12713-bib-0031){ref-type="ref"}                               Two patients:\                                                                                                        1\. 1200 mg DMC daily plus cyclophosphamide\                           DMC treatment corrected HN and hypo‐osmolality, but was discontinued in both patients owing to deterioration of renal function                                                         Potentially dangerous side effects exclude routine use of DMC\
                                                                                                1. A 51‐year‐old man with oat‐cell carcinoma of the lung. Diagnosis of SIADH\                                         2. 1200 mg DMC daily                                                                                                                                                                                                                                          Overall, DMC is effective in the treatment of SIADH, but has a potential to lead to a deterioration of renal function
                                                                                                2. A 60‐year‐old‐man with 4‐week history of confusion and drowsiness. Diagnosis of SIADH                                                                                                                                                                                                                                                                                            

  Decaux et al. 1981 [33](#ijcp12713-bib-0033){ref-type="ref"}                                  A 76‐year‐old man admitted to hospital because of grand mal seizures\                                                 A single dose of DMC\                                                  Patient had severe gastric intolerance to DMC and the drug was stopped after the first dose                                                                                            HN was controlled with furosemide after intolerance to DMC
                                                                                                SIADH diagnosed                                                                                                       Water restriction\                                                                                                                                                                                                                                            
                                                                                                                                                                                                                      Urea infusion iv\                                                                                                                                                                                                                                             
                                                                                                                                                                                                                      Furosemide                                                                                                                                                                                                                                                    

  Decaux et al. 1985 [32](#ijcp12713-bib-0032){ref-type="ref"}                                  A 62‐year‐old woman\                                                                                                  300 mg DMC twice daily                                                 DMC corrected HN but led to phosphate diabetes                                                                                                                                         Phosphate diabetes appeared after therapy with DMC and persisted for 3 months\
                                                                                                Heavy smoker reporting weakness and memory loss\                                                                                                                                                                                                                                                                                                                                    The augmentation in phosphate clearance was unrelated to serum sodium levels\
                                                                                                Diagnosis of SIADH\                                                                                                                                                                                                                                                                                                                                                                 Phosphate diabetes was related to selective DMC‐induced renal toxicity
                                                                                                Oat‐cell carcinoma                                                                                                                                                                                                                                                                                                                                                                  

  Heim et al. 1977 [34](#ijcp12713-bib-0034){ref-type="ref"}                                    75‐year‐old woman, decline in general condition and pleural effusion\                                                 DMC 1200 mg/day                                                        HN was corrected by fluid restriction; addition of DMC resulted in increased fluid clearance, but the patient developed vomiting and diarrhoea on day 4 and DMC was stopped on day 7   DMC is a relatively non‐toxic antibiotic which was shown to be effective; however, treatment was interrupted on day 8 owing to vomiting and diarrhoea\
                                                                                                (Two further cases not receiving DMC are reported)                                                                                                                                                                                                                                                                                                                                  The dose of 1200 mg/day may have been too strong for this patient

  Padfield et al. 1978 [35](#ijcp12713-bib-0035){ref-type="ref"}                                A 64‐year‐old man with SIADH following head injury and meningitis                                                     300 mg DMC four times daily followed by 600 mg DMC four times daily\   600 mg DMC four times daily rapidly corrected all biochemical features of SIADH\                                                                                                       DMC corrected the biochemical abnormalities of SIADH\
                                                                                                                                                                                                                      Fixed fluid intake                                                     Acute renal failure was possibly induced by DMC\                                                                                                                                       Possible evidence of nephrotoxicity
                                                                                                                                                                                                                                                                                             On discontinuation of DMC normal renal function returned.                                                                                                                              

  Perks et al. 1976 [36](#ijcp12713-bib-0036){ref-type="ref"}                                   A 61‐year‐old man with memory deficit\                                                                                600 mg DMC daily\                                                      Treatment with DMC led to clinical and biochemical improvement                                                                                                                         DMC is a safe and effective treatment that in this case allowed discharge from hospital\
                                                                                                Inoperable carcinoma diagnosed 7 months after original admission                                                      Fluid restriction                                                                                                                                                                                                                                             This regimen may simplify outpatient management of other patients with this syndrome

  Shimoda et al. 1986 (note, published in Japanese) [38](#ijcp12713-bib-0038){ref-type="ref"}   A 63‐year‐old woman hospitalised after losing consciousness; prior surgery for ruptured anterior artery\              900 mg/day DMC\                                                        Patient became comatose and developed quadriplegia after rapid correction of serum sodium levels\                                                                                      Computed tomography scans and brain stem auditory responses were indicative of ODS
                                                                                                Diagnosis of SIADH                                                                                                    16 mg/day dexamethasone                                                Patient died of septic shock after 12 months of hospitalisation                                                                                                                        

  Soudan and Qunibi, 2012 [39](#ijcp12713-bib-0039){ref-type="ref"}                             A 78‐year‐old woman with history of hypothyroidism, vitiligo, rheumatoid arthritis and early Alzheimer\'s dementia\   300 mg DMC three times daily.\                                         Patient developed severe HN as a result of rigid fluid restriction and DMC therapy\                                                                                                    DMC should be reserved for patients unable tolerate or unwilling to follow strict fluid restriction
                                                                                                Hospitalised with severe HN diagnosed as secondary to SIADH.                                                          Fluid restriction\                                                     Serum sodium levels stabilised after discontinuation of DMC                                                                                                                            
                                                                                                                                                                                                                      Normal saline infusion\                                                                                                                                                                                                                                       
                                                                                                                                                                                                                      Furosemide\                                                                                                                                                                                                                                                   
                                                                                                                                                                                                                      Existing medication:\                                                                                                                                                                                                                                         
                                                                                                                                                                                                                      Methotrexate\                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                      Memantine HCL\                                                                                                                                                                                                                                                
                                                                                                                                                                                                                      Mirtazapine\                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                      Sulfamethoxazole and trimethoprim                                                                                                                                                                                                                             
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

DMC, demeclocycline; HN, hypernatraemia; iv, intravenous; ODS, osmotic demyelination syndrome; SIADH, syndrome of inappropriate antidiuretic hormone secretion.

John Wiley & Sons, Ltd

RCT evidence for the effectiveness and safety of demeclocycline {#ijcp12713-sec-0014}
---------------------------------------------------------------

A comparison of demeclocycline with placebo in nine patients with chronic psychiatric illness suggested, there are no significant differences in mean serum sodium concentration after 3 weeks\' treatment (131.4 mmol/l and 134.1 mmol/l, respectively). There were no significant differences between treatments in the frequency of episodes of serum sodium levels \< 125 mmol/l (p = 0.78). All patients experienced episodes of HN during the study; no adverse events related to demeclocycline were reported [24](#ijcp12713-bib-0024){ref-type="ref"}.

Horattas et al. reported a prospective, double‐blind, placebo‐controlled study of 30 patients undergoing elective CABG. Patients were randomised to receive either placebo or demeclocycline 1200 mg/day at pre‐operative Day 5 and continuing through to postoperative Day 2. Following placebo, serum sodium concentration was significantly reduced from pre‐operative levels while serum sodium and osmolality was within normal range in the demeclocycline group (p \< 0.01); urine osmolality increased significantly with placebo on postoperative Day 1 (p = 0.04). At postoperative Day 2, serum sodium concentrations in the placebo group continued at a reduced level compared with baseline, but not with demeclocycline [25](#ijcp12713-bib-0025){ref-type="ref"}. Two patients discontinued demeclocycline owing to skin hypersensitivity and gastrointestinal upset, and four reported mild gastrointestinal upset [25](#ijcp12713-bib-0025){ref-type="ref"}. RCT data for the effectiveness and safety of demeclocycline are presented in Table [4](#ijcp12713-tbl-0004){ref-type="table-wrap"}.

###### 

Efficacy and safety results -- randomised controlled trial summary

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author, year                                                      Serum sodium (pretreatment)               Serum sodium (post treatment)             Urine sodium (pretreatment)   Urine sodium (post treatment)   AEs (total)                 AEs (individual)                                            SAEs (total)                                             Author conclusion                                                                           Comments
  ----------------------------------------------------------------- ----------------------------------------- ----------------------------------------- ----------------------------- ------------------------------- --------------------------- ----------------------------------------------------------- -------------------------------------------------------- ------------------------------------------------------------------------------------------- ------------------------------------------------------
  Alexander et al. 1991 [24](#ijcp12713-bib-0024){ref-type="ref"}   On placebo:\                              On DMC:\                                  NR                            NR                              0                           0                                                           0                                                        No significant effect of DMC on serum sodium of in psychotic patients with polydipsia‐HN.   Patients not explicitly diagnosed with SIADH
                                                                    Mean of 131.4 mmol/l in third week\       Mean of 134.1 mmol/l in third week\                                                                                                                                                                                                                                                                                                                  
                                                                    Episodes of serum sodium \<125 mmol/l,\   Episodes of serum sodium \<125 mmol/l,\                                                                                                                                                                                                                                                                                                              
                                                                    13 of 110 measurements                    10 of 103 measurements                                                                                                                                                                                                                                                                                                                               

  Horattas et al. 1998 [25](#ijcp12713-bib-0025){ref-type="ref"}    Pre‐operative:\                           Postoperative day 2:\                     NR                            NR                              Two patients discontinued   Hypersensitivity (rash) leading to discontinuation: 1/30\   No specific SAEs reported, but 2 patients discontinued   Administration of DMC can inhibit vasopressin secretion following urgery                    Postoperative length of stay was not affected by DMC
                                                                    DMC mean: 138.9 mmol/l\                   DMC mean: 138 mmol/l approx.\                                                                                                       GI upset leading to discontinuation: 1/30\                                                                                                                                                                       
                                                                    Placebo mean: 138.1 mmol/l                Placebo mean:\                                                                                                                      Mild GI upset: 4/30                                                                                                                                                                                              
                                                                                                              135.5 mmol/l approx.                                                                                                                                                                                                                                                                                                                                 
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AE, adverse event; DMC, demeclocycline; GI, gastrointestinal; HN, hyponatraemia; NR, not reported; SAE, serious adverse event; SIADH, symptom of inappropriate antidiuretic hormone secretion.

John Wiley & Sons, Ltd

Non‐randomised cohort studies of demeclocycline {#ijcp12713-sec-0015}
-----------------------------------------------

Four observational cohort studies were identified and reported a total of 39 patients with HN secondary to SIADH. All four studies reported an increase in mean serum sodium levels during treatment with demeclocycline at doses of up to 1200 mg/day [20](#ijcp12713-bib-0020){ref-type="ref"}, [22](#ijcp12713-bib-0022){ref-type="ref"}, [26](#ijcp12713-bib-0026){ref-type="ref"}, [27](#ijcp12713-bib-0027){ref-type="ref"}.

Two studies reported adverse events associated with demeclocycline, including azotemia (nine patients in total; two discontinued demeclocycline), renal function impairment (two patients) and nausea (one patient) [20](#ijcp12713-bib-0020){ref-type="ref"}, [22](#ijcp12713-bib-0022){ref-type="ref"}. Demeclocycline effectiveness and safety data reported in observational cohort studies are presented in Table [5](#ijcp12713-tbl-0005){ref-type="table-wrap"}. Two retrospective chart analyses reported the impact of demeclocycline in a further 21 patients [21](#ijcp12713-bib-0021){ref-type="ref"}, [28](#ijcp12713-bib-0028){ref-type="ref"}.

###### 

Efficacy and safety results -- cohort studies summary

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author, year                                                            Serum sodium (pretreatment)   Serum sodium (post treatment)                                                    Urine sodium (pretreatment)   Urine sodium (post treatment)   AEs (individual)                                                   SAEs (total)                                                                                                                                                 Author conclusion                                                                                                       Comments
  ----------------------------------------------------------------------- ----------------------------- -------------------------------------------------------------------------------- ----------------------------- ------------------------------- ------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------
  De Troyer et al. 1977 [20](#ijcp12713-bib-0020){ref-type="ref"}         120.4 ± 2.4 mmol/l            135.7 ± 4.2 mmol/l\                                                              NR                            NR                              One patient had a rise in blood urea level\                        NR                                                                                                                                                           Although DMC moderately impairs renal function, it appears to be the treatment of choice in the chronic form of SIADH   Clinical benefits were reported in five of seven patients
                                                                                                        (p \< 0.0005 vs before)                                                                                                                        Two patients had renal function impairment because of treatment\                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                       One patient experienced mild nausea                                                                                                                                                                                                                                                                                                                     

  Forrest et al. 1978 [26](#ijcp12713-bib-0026){ref-type="ref"}           122 mmol/l                    139 mmol/l                                                                       98 mmol/l                     40 mmol/l                       NR                                                                 NR                                                                                                                                                           DMC is superior to lithium in the treatment of SIADH and may obviate the need for severe water restriction\             Seven patients had carcinoma; one had glioma of the hypothalamus, one had a basal skull fracture and one had SIADH of unknown cause
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       No side effects were observed in this study                                                                             

  Goldman and Luchins, 1985 [27](#ijcp12713-bib-0027){ref-type="ref"}     Mean:\                        During treatment, mean: 131.9 mmol/l\                                            NR                            NR                              NR                                                                 NR                                                                                                                                                           DMC reduces the frequency and severity of HN episodes in chronic psychotics                                             Only five of eight patients met criteria for SIADH
                                                                          128.1 mmol/l                  After treatment, mean: 128.2 mmol/l                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  Perks et al. 1979 [22](#ijcp12713-bib-0022){ref-type="ref"}             118 ± 8 mmol/l                138 ± 7 mmol/l after a mean of 8.6 ± 5.3 days\                                   54 ± 24 mmol/l (*n* = 7)      29 ± 21 mmol/l\                 Eight patients developed azotemia                                  Two patients discontinued DMC owing to azotemia                                                                                                              The adverse effects of DMC may be more important than previously suggested\                                              
                                                                                                        (In six patients who discontinued, serum sodium fell to 125 ± 7 mmol/l)                                        (*n* = 7)                                                                                                                                                                                                                                                       The 1200 mg dose may be associated with an increased likelihood of impaired renal function                              

  Brewerton and Jackson, 1994 [28](#ijcp12713-bib-0028){ref-type="ref"}   Carbamazepine:\               Carbamazepine plus DMC:\                                                         NR                            NR                              NR                                                                 NR                                                                                                                                                           DMC appears to have prevented carbamazepine‐induced HN in five of six patients                                           
                                                                          130.1 ± 5.9 mmol/l            136.7 ± 6.1 mmol/l                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  Trump, 1981 [21](#ijcp12713-bib-0021){ref-type="ref"}                   119 mmol/l                    Mean peak serum sodium: 138.8 mmol/l by day 9 (peak achieved after 3--28 days)   92 mmol/l                     NR                              Azotemia:\                                                         Three patients died within 10 days of receiving DMC 1200 mg/day; causes were deemed to be advanced infections or malignancy; all three had marked azotemia   Authors suggest that renal dysfunction associated with DMC may have contributed to the deaths of three patients\        Patients not explicitly diagnosed with SIADH
                                                                                                                                                                                                                                                       Serum urea nitrogen \> 5 mg/dl: 12 of 15 patients\                                                                                                                                                                              Most (five of six) patients with severe azotemia were also receiving other nephrotoxic or antianabolic agents.          
                                                                                                                                                                                                                                                       Serum urea nitrogen \> 25 mg/dl: 6 of 15 patients                                                                                                                                                                                                                                                                                                       
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AE, adverse event; CI, confidence interval; CNS, central nervous system; DMC, demeclocycline; GI, gastrointestinal; HN, hyponatraemia; NR, not reported; SAE, serious adverse event; SIADH, symptom of inappropriate antidiuretic hormone secretion

John Wiley & Sons, Ltd

Brewerton et al. reported on six psychiatric patients with a history of carbamazepine responsiveness who developed clinically significant carbamazepine‐induced HN. Treatment with demeclocycline was associated with significant increases in serum sodium levels in five patients compared with pretreatment concentrations (increases from 130.1 to 136.7 mmol/l). Safety data were not reported in this study [28](#ijcp12713-bib-0028){ref-type="ref"}.

A retrospective review of 15 patients with malignancies treated with demeclocycline for serious HN, without a specific diagnosis of SIADH, reported an increase in mean serum sodium. From pretreatment values of 119 mmol/l, sodium levels were raised to a mean peak of 139 mmol/l after 3--28 days [21](#ijcp12713-bib-0021){ref-type="ref"}.

In total, 80% of patients (*n* = 12) developed azotemia and three died within 10 days of receiving demeclocycline. Although the deaths were because of advanced infections and malignancy, three presented with marked azotemia; the renal dysfunction associated with demeclocycline was considered as a possible contributor to the deaths. Of the six patients with severe azotemia (serum urea nitrogen \> 25 mg/dl), five patients were receiving concomitant nephrotoxic or antianabolic agents: aminoglycoside antibiotics, amphotericin B and corticosteroid [21](#ijcp12713-bib-0021){ref-type="ref"}.

Case reports involving demeclocycline {#ijcp12713-sec-0016}
-------------------------------------

Ten case reports, detailing 11 patients in total, presented safety data pertaining to demeclocycline [29](#ijcp12713-bib-0029){ref-type="ref"}, [30](#ijcp12713-bib-0030){ref-type="ref"}, [31](#ijcp12713-bib-0031){ref-type="ref"}, [32](#ijcp12713-bib-0032){ref-type="ref"}, [33](#ijcp12713-bib-0033){ref-type="ref"}, [34](#ijcp12713-bib-0034){ref-type="ref"}, [35](#ijcp12713-bib-0035){ref-type="ref"}, [36](#ijcp12713-bib-0036){ref-type="ref"}, [37](#ijcp12713-bib-0037){ref-type="ref"}, [38](#ijcp12713-bib-0038){ref-type="ref"}. Demeclocycline effectiveness and safety data reported in case studies are presented in Table [6](#ijcp12713-tbl-0006){ref-type="table-wrap"}.

###### 

Efficacy and safety results -- case reports summary

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author, year                                                                            Patient population                                                                                                    Interventions                                                          Outcome                                                                                                                                                                                      Author conclusion
  --------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------
  Antonelli et al. 1993 [29](#ijcp12713-bib-0029){ref-type="ref"}                         A 59‐year‐old man; slight fever, dyspnoea, weight loss, asthenia and mental slowness                                  300 mg DMC twice daily for about 3 weeks\                              Patient developed phosphate diabetes after 4 days of DMC Progressive amelioration of the symptomatology and resolution of SIADH after DMC discontinuation and the start of corticosteroids   Phosphate diabetes may be related to selective DMC‐induced tubulopathy
                                                                                                                                                                                                                Water restriction\                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                Hypertonic saline iv\                                                                                                                                                                                                                                               
                                                                                                                                                                                                                Corticosteroid treatment for 10 months.                                                                                                                                                                                                                             

  Curtis et al. 2002 [30](#ijcp12713-bib-0030){ref-type="ref"}                            A 94‐year‐old man hospitalised following collapse\                                                                    300 mg DMC three times daily plus fluid restriction\                   Fatal acute renal failure                                                                                                                                                                    Short‐term DMC can effectively control symptomatic HN but caution is required because of its potential nephrotoxicity\
                                                                                          Diagnosis of SIADH                                                                                                    Nine days after admission, DMC increased to four times daily\                                                                                                                                                                                                       Authors note a danger of dehydration in patients whose fluid intake has become compromised\
                                                                                                                                                                                                                Metronizadole\                                                                                                                                                                                                                                                      Authors suggest that had DMC been discontinued once the HN had resolved, the development of acute renal failure would have been avoided
                                                                                                                                                                                                                Benzydamine hydrochloride mouth washes                                                                                                                                                                                                                              

  Danovitch et al. 1978 [31](#ijcp12713-bib-0031){ref-type="ref"}                         Two patients:\                                                                                                        1\. 1200 mg DMC daily plus cyclophosphamide\                           DMC treatment corrected HN and hypo‐osmolality but was discontinued in both patients owing to deterioration of renal function                                                                Potentially dangerous side effects exclude routine use of DMC\
                                                                                          1. A 51‐year‐old man with oat‐cell carcinoma of the lung. Diagnosis of SIADH\                                         2. 1200 mg DMC daily                                                                                                                                                                                                                                                Overall, DMC is effective in the treatment of SIADH, but has a potential to lead to a deterioration of renal function
                                                                                          2. A 60‐year‐old‐man with 4‐week history of confusion and drowsiness. Diagnosis of SIADH                                                                                                                                                                                                                                                                                                  

  Decaux et al. 1981 [33](#ijcp12713-bib-0033){ref-type="ref"}                            A 76‐year‐old man admitted to hospital because of grand mal seizures\                                                 A single dose of DMC\                                                  Patient had severe gastric intolerance to DMC and the drug was stopped after the first dose                                                                                                  HN was controlled with furosemide after intolerance to DMC
                                                                                          SIADH diagnosed                                                                                                       Water restriction\                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                Urea infusion iv\                                                                                                                                                                                                                                                   
                                                                                                                                                                                                                Furosemide                                                                                                                                                                                                                                                          

  Decaux et al. 1985 [32](#ijcp12713-bib-0032){ref-type="ref"}                            A 62‐year‐old woman\                                                                                                  300 mg DMC twice daily                                                 DMC corrected HN but led to phosphate diabetes                                                                                                                                               Phosphate diabetes appeared after therapy with DMC and persisted for 3 months\
                                                                                          Heavy smoker reporting weakness and memory loss\                                                                                                                                                                                                                                                                                                                                          The augmentation in phosphate clearance was unrelated to serum sodium levels\
                                                                                          Diagnosis of SIADH\                                                                                                                                                                                                                                                                                                                                                                       Phosphate diabetes was related to selective DMC‐induced renal toxicity
                                                                                          Oat‐cell carcinoma                                                                                                                                                                                                                                                                                                                                                                        

  Heim et al. 1977 [34](#ijcp12713-bib-0034){ref-type="ref"}                              75‐year‐old woman, decline in general condition and pleural effusion\                                                 DMC 1200 mg/day                                                        HN was corrected by fluid restriction; addition of DMC resulted in increased fluid clearance, but the patient developed vomiting and diarrhoea on day 4 and DMC was stopped on day 7         DMC is a relatively non‐toxic antibiotic which was shown to be effective; however, treatment was interrupted on day 8 owing to vomiting and diarrhoea\
                                                                                          (Two further cases not receiving DMC are reported)                                                                                                                                                                                                                                                                                                                                        The dose of 1200 mg/day may have been too strong for this patient

  Padfield et al. 1978 [35](#ijcp12713-bib-0035){ref-type="ref"}                          A 64‐year‐old man with SIADH following head injury and meningitis                                                     300 mg DMC four times daily followed by 600 mg DMC four times daily\   600 mg DMC four times daily rapidly corrected all biochemical features of SIADH\                                                                                                             DMC corrected the biochemical abnormalities of SIADH\
                                                                                                                                                                                                                Fixed fluid intake                                                     Acute renal failure was possibly induced by DMC\                                                                                                                                             Possible evidence of nephrotoxicity
                                                                                                                                                                                                                                                                                       On discontinuation of DMC normal renal function returned.                                                                                                                                    

  Perks et al. 1976 [36](#ijcp12713-bib-0036){ref-type="ref"}                             A 61‐year‐old man with memory deficit\                                                                                600 mg DMC daily\                                                      Treatment with DMC led to clinical and biochemical improvement                                                                                                                               DMC is a safe and effective treatment that in this case allowed discharge from hospital\
                                                                                          Inoperable carcinoma diagnosed 7 months after original admission                                                      Fluid restriction                                                                                                                                                                                                                                                   This regimen may simplify outpatient management of other patients with this syndrome

  Shimoda et al. 1986 (published in Japanese) [38](#ijcp12713-bib-0038){ref-type="ref"}   A 63‐year‐old woman hospitalised after losing consciousness; prior surgery for ruptured anterior artery\              900 mg/day DMC\                                                        Patient became comatose and developed quadriplegia after rapid correction of serum sodium levels\                                                                                            Computed tomography scans and brain stem auditory responses were indicative of ODS
                                                                                          Diagnosis of SIADH                                                                                                    16 mg/day dexamethasone                                                Patient died of septic shock after 12 months of hospitalisation                                                                                                                              

  Soudan and Qunibi, 2012 [39](#ijcp12713-bib-0039){ref-type="ref"}                       A 78‐year‐old woman with history of hypothyroidism, vitiligo, rheumatoid arthritis and early Alzheimer\'s dementia\   300 mg DMC three times daily.\                                         Patient developed severe HN as a result of rigid fluid restriction and DMC therapy\                                                                                                          DMC should be reserved for patients unable tolerate or unwilling to follow strict fluid restriction
                                                                                          Hospitalised with severe HN diagnosed as secondary to SIADH.                                                          Fluid restriction\                                                     Serum sodium levels stabilised after discontinuation of DMC                                                                                                                                  
                                                                                                                                                                                                                Normal saline infusion\                                                                                                                                                                                                                                             
                                                                                                                                                                                                                Furosemide\                                                                                                                                                                                                                                                         
                                                                                                                                                                                                                Existing medication:\                                                                                                                                                                                                                                               
                                                                                                                                                                                                                Methotrexate\                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                Memantine HCL\                                                                                                                                                                                                                                                      
                                                                                                                                                                                                                Mirtazapine\                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                Sulfamethoxazole and trimethoprim                                                                                                                                                                                                                                   
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

DMC, demeclocycline; HN, hyponatraemia; ODS, osmotic demyelination syn drome; SIADH, syndrome of inappropriate antidiuretic hormone secretion.
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Three reports associated deterioration in renal function with demeclocycline in four patients with a diagnosis of SIADH [30](#ijcp12713-bib-0030){ref-type="ref"}, [31](#ijcp12713-bib-0031){ref-type="ref"}, [35](#ijcp12713-bib-0035){ref-type="ref"}. Distinct but reversible episodes of glomerular filtration rate (GFR) reduction were observed in two patients [31](#ijcp12713-bib-0031){ref-type="ref"}, with acute renal failure reported in a third receiving demeclocycline at up to 2400 mg/day [35](#ijcp12713-bib-0035){ref-type="ref"}. A fourth patient (94‐year‐old male hospitalised following collapse and subsequent diagnosis of SIADH) died of irreversible acute renal failure that authors attributed to dehydration associated with demeclocycline 1200 mg/day and a compromised fluid intake [30](#ijcp12713-bib-0030){ref-type="ref"}.

Two case reports described the development of hyperphosphaturia during demeclocycline treatment for HN secondary to SIADH. Upon follow‐up, both patients presented with malignancies considered related to elevated phosphate levels, which recovered following discontinuation of demeclocycline. Authors of both reports considered the phosphate diabetes related to selective demeclocycline‐induced renal toxicity [29](#ijcp12713-bib-0029){ref-type="ref"}, [32](#ijcp12713-bib-0032){ref-type="ref"}.

A further two reports describe severe gastric intolerance leading to discontinuation of demeclocycline [33](#ijcp12713-bib-0033){ref-type="ref"}, [34](#ijcp12713-bib-0034){ref-type="ref"}. In one case, a 76‐year‐old male admitted with grand mal seizures and a previous history of peptic ulcer, severe gastric intolerance occurred after a single dose of demeclocycline [33](#ijcp12713-bib-0033){ref-type="ref"}.

A single case study of a 61‐year‐old male with SIADH reported normalisation of serum sodium levels with demeclocycline (600 mg/day). After a month, demeclocycline was discontinued but followed by a rapid fall in both osmolality and level of consciousness. Reinstitution of treatment led to biochemical and clinical improvement; the patient was discharged on demeclocycline 3 months after admission [36](#ijcp12713-bib-0036){ref-type="ref"}.

A Japanese report of a 63‐year‐old female with SIADH treated by strict water restriction, and administration of sodium, dexamethasone and demeclocycline, highlights correction of serum sodium from 93 to 137 mmol/l within 3 days of treatment. Subsequently, the patient became comatose and developed quadriplegia. After 12 months of hospitalisation, the patient died of septic shock. Computed tomography scans and brain stem auditory responses were indicative of ODS [38](#ijcp12713-bib-0038){ref-type="ref"}. Data for this case study were obtained from the English language abstract and figures presented within the report.

A final study reported seizures and altered mental state in a 78‐year‐old female patient with a history of hypothyroidism, rheumatoid arthritis and early Alzheimer\'s disease admitted for severe HN, which was considered secondary to SIADH. The patient was treated with demeclocycline (900 mg/day) and discharged under fluid restriction. After 6 weeks, she was readmitted; laboratory investigation identified severe hypernatraemia (serum sodium, 185 mmol/l) resulting from over‐correction of HN. The authors recommended that demeclocycline should be reserved for patients for whom strict fluid restriction is unsuitable [39](#ijcp12713-bib-0039){ref-type="ref"}.

Discussion {#ijcp12713-sec-0017}
==========

Hyponatraemia can lead to a wide spectrum of clinical symptoms and presents in a range of conditions. Despite this, the diagnosis and management of patients remains problematic [1](#ijcp12713-bib-0001){ref-type="ref"}, [3](#ijcp12713-bib-0003){ref-type="ref"}, particularly because of the heterogeneous nature of HN [40](#ijcp12713-bib-0040){ref-type="ref"}. In addition, treatment guidance has been generally oversimplistic, without clear consensus, and not reflective of the range of clinical issues encountered in current daily practice [1](#ijcp12713-bib-0001){ref-type="ref"}.

The literature search and review demonstrates a paucity of available high‐quality data for the effectiveness and safety of demeclocycline in the treatment of HN secondary to SIADH; no relevant economic evaluations or HRQoL studies were identified. With the exception of case reports, no published studies have addressed the use of demeclocycline for SIADH‐associated HN for more than 15 years [20](#ijcp12713-bib-0020){ref-type="ref"}, [22](#ijcp12713-bib-0022){ref-type="ref"}, [24](#ijcp12713-bib-0024){ref-type="ref"}, [25](#ijcp12713-bib-0025){ref-type="ref"}, [26](#ijcp12713-bib-0026){ref-type="ref"}, [27](#ijcp12713-bib-0027){ref-type="ref"}. Despite its long history in the treatment of HN secondary to SIADH, the use of demeclocycline is largely based on clinical experience rather than objective evidence. Although a lack of robust evidence from RCTs is by no means uncommon in medicine, a systematic appraisal of all published studies and case reports was necessary to appraise the efficacy and safety of demeclocycline treatment.

Examining the studies that are available, only two compared demeclocycline with placebo [24](#ijcp12713-bib-0024){ref-type="ref"}, [25](#ijcp12713-bib-0025){ref-type="ref"}. Of these RCTs, one did not demonstrate any significant differences in mean serum sodium levels after 3‐weeks\' treatment. However, this study enrolled patients with psychosis and episodic or chronic polydipsia‐associated HN (mean duration of 5.4 years) who did not have a specific diagnosis of SIADH [24](#ijcp12713-bib-0024){ref-type="ref"}. In addition, the dosing ranges of demeclocycline were initially relatively low (escalating from 600 mg/day to 1200 mg/day by week 3), compared with the recommended initial dose of 900--1200 mg/day [18](#ijcp12713-bib-0018){ref-type="ref"}. The second RCT identified also included patients without a diagnosis of SIADH, but concluded that demeclocycline prevented HN because of increased secretion of ADH, commonly seen in patients undergoing CABG procedures [25](#ijcp12713-bib-0025){ref-type="ref"}.

The mode of action of demeclocycline on ADH‐induced water flow is not well understood, but the mechanism of therapeutic effect involves induction of nephrogenic diabetes insipidus [12](#ijcp12713-bib-0012){ref-type="ref"}, [41](#ijcp12713-bib-0041){ref-type="ref"}. While no studies have systematically evaluated the side effects associated with demeclocycline, several studies have identified safety issues associated with the onset of nephrogenic diabetes insipidus, particularly renal dysfunction [20](#ijcp12713-bib-0020){ref-type="ref"}, [21](#ijcp12713-bib-0021){ref-type="ref"}, [22](#ijcp12713-bib-0022){ref-type="ref"}, [30](#ijcp12713-bib-0030){ref-type="ref"}, [31](#ijcp12713-bib-0031){ref-type="ref"}, [35](#ijcp12713-bib-0035){ref-type="ref"}. In some patients, polyuria can be profound and patients can become markedly symptomatic, occasionally developing hypernatraemia if access to water is severely restricted [12](#ijcp12713-bib-0012){ref-type="ref"}, [39](#ijcp12713-bib-0039){ref-type="ref"}. Patients with known liver disease should not receive more than 1 g/day demeclocycline [18](#ijcp12713-bib-0018){ref-type="ref"}. In addition, monitoring of both renal and hepatic function should be performed regularly [18](#ijcp12713-bib-0018){ref-type="ref"}, [42](#ijcp12713-bib-0042){ref-type="ref"}.

Onset of action for demeclocycline is unpredictable and reported to range from 2 to 5 days, complicating dose adjustments [12](#ijcp12713-bib-0012){ref-type="ref"}, [16](#ijcp12713-bib-0016){ref-type="ref"}. Two reports describe severe gastric intolerance leading to treatment discontinuation [33](#ijcp12713-bib-0033){ref-type="ref"}, [34](#ijcp12713-bib-0034){ref-type="ref"}; one incident occurred following a single dose of demeclocycline in a 76‐year‐old male with grand mal seizures and SIADH. Authors suggested a 1200 mg/day dose may have been too high for the second patient: a 75‐year‐old woman with decline in general condition and pleural effusion who developed vomiting and diarrhoea on Day 4 of treatment [33](#ijcp12713-bib-0033){ref-type="ref"}.

Overall, most reports suggest that demeclocycline is able to increase serum sodium levels in the majority (60%) of patients with HN secondary to SIADH [12](#ijcp12713-bib-0012){ref-type="ref"}; treatment effectiveness in patients without a specific SIADH diagnosis may be limited [24](#ijcp12713-bib-0024){ref-type="ref"}. The safety profile of demeclocycline appears variable with the potential for complications, such as severe hypernatraemia [39](#ijcp12713-bib-0039){ref-type="ref"} and renal dysfunction [18](#ijcp12713-bib-0018){ref-type="ref"}. Recent European clinical practice guidelines for diagnosis and treatment of HN recommend against the use of demeclocycline [1](#ijcp12713-bib-0001){ref-type="ref"}. Thus, close monitoring may be warranted in patients receiving demeclocycline for HN secondary to SIADH.

Conclusions {#ijcp12713-sec-0018}
===========

The results from this systematic literature review highlight the paucity of clinical evidence and lack of economic evidence supporting the use of demeclocycline for HN secondary to SIADH. There is a clinical need to treat HN and manage patients with SIADH appropriately [3](#ijcp12713-bib-0003){ref-type="ref"}; in particular, the management of patients with cancer. For example, chemotherapy may need to be delayed until the normalisation of these patients\' sodium levels [43](#ijcp12713-bib-0043){ref-type="ref"}, and delays to chemotherapy negatively influence outcomes [44](#ijcp12713-bib-0044){ref-type="ref"}. In addition, some chemotherapy regimens require aggressive hydration strategies [42](#ijcp12713-bib-0042){ref-type="ref"}, [45](#ijcp12713-bib-0045){ref-type="ref"}. Furthermore, patients may also require hospital admission for the symptomatic consequences of HN, adding to the burden of their cancer [42](#ijcp12713-bib-0042){ref-type="ref"}, [46](#ijcp12713-bib-0046){ref-type="ref"}, [47](#ijcp12713-bib-0047){ref-type="ref"}.

Although most reports suggest that demeclocycline can address serum sodium levels in HN [12](#ijcp12713-bib-0012){ref-type="ref"}, efficacy in patients without SIADH may be limited [24](#ijcp12713-bib-0024){ref-type="ref"}. Moreover, with a variable and unreliable time to onset of action, and a safety profile associated with induction of nephrogenic diabetes insipidus, demeclocycline dose adjustments can be complex [12](#ijcp12713-bib-0012){ref-type="ref"}, [16](#ijcp12713-bib-0016){ref-type="ref"}. Thus, it may be concluded that patients receiving demeclocycline for HN secondary to SIADH must be closely monitored.
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**Embase\#SearchesResults**\#1exp inappropriate vasopressin secretion/2829\#2syndrome of inappropriate antidiuretic.mp.1001\#3(inappropriate antidiuretic adj3 syndrome).mp.1057\#4syndrome of immoderate antidiuresis.mp.0\#5schwartz‐bartter syndrome.mp.754\#6hyponatraemia.mp. or exp hyponatraemia/20,570\#7hyponatraemia.mp.2274\#8sodium ion concentration.mp.261\#9sodium serum.mp.165\#10sodium blood level.mp. or exp sodium blood level/9734\#11hypovolemia.mp. or exp hypovolemia/11,630\#12hypovolaemia.mp.1263\#13serum osmolality.mp. or exp serum osmolality/2409\#14urine osmolality.mp. or exp urine osmolality/4223\#15(osmolar or osmolarity).mp.23,152\#16exp demeclocycline/ or demeclocycline.mp.2151\#17declomycin.mp.98\#18declostatin.mp. or exp demeclocycline plus nystatin/0\#19ledermycin.mp.159\#20demeclotetracycline.mp.4\#21(Demeclor or Elkamicina or Fidocin or Mexocine or Novotriclina or Perciclina or Rynabron).mp.17\#221 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 1566,834\#2316 or 17 or 18 or 19 or 20 or 212168**\#24\#22 and \#23517** **Medline & Medline In‐Process\#SearchesResults**\#1exp Inappropriate ADH Syndrome/ or inappropriate vasopressin secretion.mp.2,275\#2syndrome of inappropriate antidiuretic.mp.754\#3(inappropriate antidiuretic adj3 syndrome).mp.811\#4syndrome of immoderate antidiuresis.mp.0\#5schwartz‐bartter syndrome.mp.97\#6hyponatraemia.mp. or exp hyponatraemia/9,892\#7hyponatraemia.mp.1,707\#8sodium ion concentration.mp.231\#9sodium serum.mp.104\#10sodium blood level.mp.2\#11hypovolemia.mp. or exp Hypovolemia/3,954\#12exp Hypovolemia/ or hypovolaemia.mp.1,926\#13hypovolaemia.mp.983\#14exp Osmolar Concentration/ or serum osmolality.mp.60,404\#15exp Osmolar Concentration/ or ((serum or urine) and osmolality).mp.62,530\#16(osmolar or osmolarity).mp.53,453\#171 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 1682,327\#18demeclocycline.mp. or exp Demeclocycline/894\#19declomycin.mp.13\#20declostatin.mp.0\#21ledermycin.mp.23\#22demeclotetracycline.mp.1\#23Demeclocyclinum.mp.0\#24(Demeclor or Elkamicina or Fidocin or Mexocine or Novotriclina or Perciclina or Rynabron).mp.4\#2518 or 19 or 20 or 21 or 22 or 23 or 24915**\#26\#17 and \#25156** **Cochrane Library\#SearchesResults**\#1MeSH descriptor: \[Inappropriate ADH Syndrome\] explode all trees9\#2inappropriate vasopressin secretion25\#3syndrome of inappropriate antidiuretic19\#4(inappropriate antidiuretic near/3 syndrome)16\#5syndrome of immoderate antidiuresis0\#6schwartz‐bartter syndrome0\#7MeSH descriptor: \[Hyponatraemia\] explode all trees107\#8hyponatraemia or hyponatraemia526\#9sodium ion concentration634\#10sodium serum2935\#11sodium blood level3870\#12MeSH descriptor: \[Hypovolemia\] explode all trees71\#13hypovolemia or hypovolaemia349\#14MeSH descriptor: \[Osmolar Concentration\] explode all trees1233\#15serum osmolality298\#16((serum or urine) and osmolality)503\#17osmolar or osmolarity1638\#18\#1 or \#2 or \#3 or \#4 or \#5 or \#6 or \#7 or \#8 or \#9 or \#10 or \#11 or \#12 or \#13 or \#14 or \#15 or \#16 or \#178019\#19MeSH descriptor: \[Demeclocycline\] explode all trees45\#20demeclocycline68\#21declomycin or declostatin0\#22ledermycin or demeclotetracycline or Demeclocyclinum12\#23Demeclor or Elkamicina or Fidocin or Mexocine or Novotriclina or Perciclina or Rynabron0\#24\#19 or \#20 or \#21 or \#22 or \#2378**\#25\#18 and \#246**
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**Summaries of excluded full‐length papersReferenceExclusion reason**Boissonnas A, Casassus P, Caquet R, Laroche C. Hyponatraemia in a cirrhotic suffering from late cutaneous porphyria: A drug to avoid, demeclocycline. \[French\]. Nouvelle Presse Medicale 1979; 8(3): 210.Not SIADHBurst V, Verbalis J, Greenberg A et al. Hyponatraemia in the hospital setting: Interim results from a prospective, observational, multi‐center, global registry. Pneumologie Conference 2013; 54.Conference abstract -- no full text availableCawley MJ. Hyponatraemia: Current treatment strategies and the role of vasopressin antagonists. Annals of Pharmacotherapy 2007; 41(5): 840--50.Review with no relevant dataJellett L, O\'Hare J, McAleese J. Syndrome of inappropriate antidiuretic hormone (SIADH) in patients with small cell lung cancer & incidence and response to treatment. Lung Cancer 2011;Conference: 9th Annual BTOG Conference 2011 Dublin Ireland. Conference Publication: 71: S41.Conference abstract -- no full text availableKamoi K, Ebe T, Kobayashi O et al. Atrial natriuretic peptide in patients with the syndrome of inappropriate antidiuretic hormone secretion and with diabetes insipidus. Journal of Clinical Endocrinology and Metabolism 1990; 70(5):1385--90.Small case study -- three patients treated and no safety issues reportedKamoi K, Toyama M, Takagi M et al. Osmoregulation of vasopressin secretion in patients with the syndrome of inappropriate antidiuresis associated with central nervous system disorders. Endocrine Journal 1999; 46(2): 269--77.No specific demeclocycline resultsLaszlo FA, Varga C, Doczi T. Cerebral oedema after subarachnoid haemorrhage. Pathogenetic significance of vasopressin. Acta Neurochirurgica 1995; 133 (3--4): 122--33.No treatment dataMiller PD, Linas SL, Schrier RW. Plasma demeclocycline levels and nephrotoxicity. Correlation in hyponatremic cirrhotic patients. JAMA 1980; 243(24): 2513--5.Not SIADHNagler EV, Haller MC, Van Biesen W et al. Treatments for chronic hyponatraemia: A systematic review of randomised controlled trials. Nephrology Dialysis Transplantation 2013;Conference: 50th ERA‐EDTA Congress Istanbul Turkey. Conference Publication: 28: i387.Conference abstract -- no full text availablePhilip T, Souillet G, Gharib C et al. Inappropriate secretion of antiduiuretic hormone during acute leukaemia treated with vincristine. Two cases (author\'s transl). \[French\]. La Nouvelle presse medicale 1979; 8(26): 2181--5.Small case study -- one patients treated and no safety issues reportedShakher J, Thompson J. Tolvaptan cost effective treatment of SIADH in malignancies. Lung Cancer 2013;Conference: 11th Annual British Thoracic Oncology Group Conference, BTOG 2013 Dublin Ireland. Conference Publication: 79: S66.Conference abstract -- no full text availableWalter HS, Ahmed SI. The incidence of hyponatraemia in small cell lung cancer: Prognostic and predictive potential in a retrospective single centre analysis. Lung Cancer 2013;Conference: 11th Annual British Thoracic Oncology Group Conference, BTOG 2013 Dublin Ireland. Conference Publication: 79: S65--S6.Conference abstract -- no full text available
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**Quality assessment of included randomised controlled trialsQuality assessment questionYes/No/Unclear/NANotesAlexander RC et al. 1991** [24](#ijcp12713-bib-0024){ref-type="ref"}** Internal validity**Does the study address an appropriate and clearly focused question?YesQuote: 'we undertook a double‐blind, placebo‐controlled study of demeclocycline in psychiatric patients with polydipsia‐hyponatraemia'Is the assignment of subjects to treatment groups randomised?YesOrder of treatment was randomly assigned; study used a cross‐over methodIs an adequate concealment method used?UnclearStudy was double‐blind and placebo‐controlled, but details on method of concealment were unclearAre subjects and investigators kept 'blind' about treatment allocation?UnclearStudy was double‐blind and placebo‐controlled, but details on method of blinding were unclearAre the treatment and control groups similar at the start of the trial?NACrossover design, not applicableIs the only difference between groups the treatment under investigation?YesCrossover design; groups are identical aside from order of treatmentAre all relevant outcomes measured in a standard, valid and reliable way?YesQuote: 'serum sodium levels were obtained in the morning twice a week (routine sodium levels) and also following episodes of acute weight gain (sporadic sodium levels)'Further details on serum sampling and sodium measurement not providedWhat percentage of the individuals or clusters recruited into each treatment arm of the study dropped out before the study was completed?No patients dropped outAre all the subjects analysed in the groups to which they were randomly allocated (often referred to as intention‐to‐treat analysis)?NACrossover design, not applicableWhere the study is carried out at more than one site, are results comparable for all sites?NASingle site study** Overall assessment**How well was the study done to minimise bias? (high quality/acceptable/reject)Taking into account clinical considerations, your evaluation of the methodology used, and the statistical power of the study, are you certain that the overall effect is due to the study intervention?Are the results of this study directly applicable to the patient group targeted by this guideline?**Horratas MC et al. 1998** [25](#ijcp12713-bib-0025){ref-type="ref"}** Internal validity**Does the study address an appropriate and clearly focused question?Is the assignment of subjects to treatment groups randomised?YesPatients were randomly assigned to treatment or placebo; details of exact method used to randomise not reportedIs an adequate concealment method used?UnclearStudy was double‐blind and placebo‐controlled, but details on method of concealment were unclearAre subjects and investigators kept 'blind' about treatment allocation?YesQuote: 'Neither the patients, caregivers, nor the investigators were aware of the assigned patient group. The study was blinded until its completion.'Are the treatment and control groups similar at the start of the trial?UnclearNo summary of baseline characteristics providedQuote: 'the two groups remained matched for age, sex, and weight'Is the only difference between groups the treatment under investigation?UnclearExclusion criteria were defined and many patients not included if they had certain comorbidities, but insufficient information provided on baseline characteristics of included patientsAre all relevant outcomes measured in a standard, valid and reliable way?UnclearLimited information on outcome collection; authors state there is no commercial assay for demeclocyclineWhat percentage of the individuals or clusters recruited into each treatment arm of the study dropped out before the study was completed?Two patients in the demeclocycline group discontinued (2/15; 13.3%); no patients in the placebo group discontinuedAre all the subjects analysed in the groups to which they were randomly allocated (often referred to as intention‐to‐treat analysis)?NoNo mention of intention‐to‐treat analysis analysis; it appears the two patients who dropped out were not included in the analysisWhere the study is carried out at more than one site, are results comparable for all sites?NASingle site study** Overall assessment**How well was the study done to minimise bias? (high quality/acceptable/reject)Taking into account clinical considerations, your evaluation of the methodology used, and the statistical power of the study, are you certain that the overall effect is due to the study intervention?Are the results of this study directly applicable to the patient group targeted by this guideline? **Quality assessment of included cohort studiesQuality assessment questionYes/No/UnclearNotesBrewerton T et al. 1994** [28](#ijcp12713-bib-0028){ref-type="ref"}** Internal validity**Does the study address an appropriate and clearly focused question?YesQuote: 'We would like to extend these observations of demeclocycline\'s reversal of carbamazepine‐induced hyponatraemia in a group of six psychiatric inpatients'Are the two groups being studied selected from source populations that are comparable in all respects other than the factor under investigation?NASingle cohort/case series; no controlsDoes the study indicate how many of the people asked to take part did so, in each of the groups being studied?NARetrospective analysis of single cohort/case series; no controlsIs the likelihood that some eligible subjects might have the outcome at the time of enrolment assessed and taken into account in the analysis?NAAll patients had a diagnosis of hyponatraemia (\< 135 mmol/l) while taking carbamazepine and were subsequently treated with demeclocyclineWhat percentage of the individuals or clusters recruited into each treatment arm of the study dropped out before the study was completed? Retrospective analysis; all patients completedIs the comparison made between full participants and those lost to follow up, by exposure status?NANo patients lost to follow‐upAre the outcomes clearly defined?Yes Is the assessment of outcome made blind to exposure status? (if the study is retrospective this may not be applicable)NARetrospective analysisWhere blinding was not possible, is there some recognition that knowledge of exposure status could have influenced the assessment of outcome?No Is the method of assessment of exposure is reliable?YesChart reviewIs evidence from other sources used to demonstrate that the method of outcome assessment is valid and reliable?No Is the exposure level or prognostic factor assessed more than once?No Are the main potential confounders identified and taken into account in the design and analysis?No Have confidence intervals been provided?NoConfidence intervals not provided but standard deviations reported**De Troyer A, 1977** [20](#ijcp12713-bib-0020){ref-type="ref"}** Internal validity**Does the study address an appropriate and clearly focused question?YesAim of study was to test 'the efficacy of demeclocycline hydrochloride in suppressing the tubular action of tumoral antidiuretic products'Are the two groups being studied selected from source populations that are comparable in all respects other than the factor under investigation?NASingle cohort/case series; no controlsDoes the study indicate how many of the people asked to take part did so, in each of the groups being studied?NoPatients were consecutive, but unclear if any patients were asked to take part and did not provide consentIs the likelihood that some eligible subjects might have the outcome at the time of enrolment assessed and taken into account in the analysis?NAAll patients had SIADH at the start of the trial; no separate control groupWhat percentage of the individuals or clusters recruited into each treatment arm of the study dropped out before the study was completed?No patients lost to follow‐upIs the comparison made between full participants and those lost to follow up, by exposure status?NANo patients lost to follow‐upAre the outcomes clearly defined?YesIs the assessment of outcome made blind to exposure status? (if the study is retrospective this may not be applicable)NoWhere blinding was not possible, is there some recognition that knowledge of exposure status could have influenced the assessment of outcome?NoIs the method of assessment of exposure is reliable?YesNo other therapy given throughout the study; fluid and sodium intake *ad libitum*Is evidence from other sources used to demonstrate that the method of outcome assessment is valid and reliable?NoIs the exposure level or prognostic factor assessed more than once?NoAre the main potential confounders identified and taken into account in the design and analysis?NoHave confidence intervals been provided?NoConfidence intervals not provided but standard deviations reported**Forrest JN et al. 1978** [26](#ijcp12713-bib-0026){ref-type="ref"}** Internal validity**Does the study address an appropriate and clearly focused question?YesQuote: 'We compared the responses to demeclocycline and lithium in a series of 10 patients with \[SIADH\]'Are the two groups being studied selected from source populations that are comparable in all respects other than the factor under investigation?NASingle cohort/case series; no controlsDoes the study indicate how many of the people asked to take part did so, in each of the groups being studied?NARetrospective analysis of single cohort/case series; no controlsIs the likelihood that some eligible subjects might have the outcome at the time of enrolment assessed and taken into account in the analysis?NAAll patients had chronic SIADH as identified by medical recordsWhat percentage of the individuals or clusters recruited into each treatment arm of the study dropped out before the study was completed?Retrospective analysis; all patients completedIs the comparison made between full participants and those lost to follow up, by exposure status?NANo patients lost to follow‐upAre the outcomes clearly defined?YesIs the assessment of outcome made blind to exposure status? (if the study is retrospective this may not be applicable)NoRetrospective analysisWhere blinding was not possible, is there some recognition that knowledge of exposure status could have influenced the assessment of outcome?NoIs the method of assessment of exposure is reliable?YesChart reviewIs evidence from other sources used to demonstrate that the method of outcome assessment is valid and reliable?NoIs the exposure level or prognostic factor assessed more than once?NoAre the main potential confounders identified and taken into account in the design and analysis?NoSome patients received lithium prior to demeclocycline and others did not; unclear if proper washout period undertakenHave confidence intervals been provided?NoConfidence intervals not provided but standard errors of the mean reported (graph only)**Goldman MB et al. 1985** [27](#ijcp12713-bib-0027){ref-type="ref"}** Internal validity**Does the study address an appropriate and clearly focused question?YesThe study attempts to replicate previous findings from a case report using a larger sample sizeAre the two groups being studied selected from source populations that are comparable in all respects other than the factor under investigation?NASingle cohort/case series; no controlsDoes the study indicate how many of the people asked to take part did so, in each of the groups being studied?UnclearUnclear if any patients refused to participateIs the likelihood that some eligible subjects might have the outcome at the time of enrolment assessed and taken into account in the analysis?UnclearAll patients had hyponatraemia at time of enrolment but only 5/8 met criteria for SIADHWhat percentage of the individuals or clusters recruited into each treatment arm of the study dropped out before the study was completed?No patients lost to follow‐upIs the comparison made between full participants and those lost to follow up, by exposure status?NANo patients lost to follow‐upAre the outcomes clearly defined?YesIs the assessment of outcome made blind to exposure status? (if the study is retrospective this may not be applicable)NoWhere blinding was not possible, is there some recognition that knowledge of exposure status could have influenced the assessment of outcome?NoIs the method of assessment of exposure is reliable?YesIs evidence from other sources used to demonstrate that the method of outcome assessment is valid and reliable?NoIs the exposure level or prognostic factor assessed more than once?NoAre the main potential confounders identified and taken into account in the design and analysis?NoHave confidence intervals been provided?NoConfidence intervals not provided but standard deviations reported**Perks WH et al. 1979** [22](#ijcp12713-bib-0022){ref-type="ref"}** Internal validity**Does the study address an appropriate and clearly focused question?YesThe authors determined the effect of demeclocycline on patients with SIADH, especially renal functionAre the two groups being studied selected from source populations that are comparable in all respects other than the factor under investigation?NASingle cohort/case series; no controlsDoes the study indicate how many of the people asked to take part did so, in each of the groups being studied?UnclearUnclear if any patients refused to participateIs the likelihood that some eligible subjects might have the outcome at the time of enrolment assessed and taken into account in the analysis?NAAll patients had SIADH based on specific criteriaWhat percentage of the individuals or clusters recruited into each treatment arm of the study dropped out before the study was completed?7/14 patients (50%) discontinued, including one death, however it appears that all patients were taking demeclocycline at the analysis timepoint of 10 daysIs the comparison made between full participants and those lost to follow up, by exposure status?UnclearOnly comparison between serum sodium levels in all patients (pre‐discontinuation) are compared with levels in patients who discontinuedAre the outcomes clearly defined?YesIs the assessment of outcome made blind to exposure status? (if the study is retrospective this may not be applicable)NoWhere blinding was not possible, is there some recognition that knowledge of exposure status could have influenced the assessment of outcome?NoIs the method of assessment of exposure is reliable?YesIs evidence from other sources used to demonstrate that the method of outcome assessment is valid and reliable?NoIs the exposure level or prognostic factor assessed more than once?NoAre the main potential confounders identified and taken into account in the design and analysis?UnclearDiscontinuation is taken into account during analysis; no indication of other confounding factors accounted forHave confidence intervals been provided?NoConfidence intervals not provided but standard deviations reported**Trump DL et al. 1981** [21](#ijcp12713-bib-0021){ref-type="ref"}** Internal validity**Does the study address an appropriate and clearly focused question?YesTo assess the efficacy of demeclocycline in the treatment of patients with water intoxication and cancerAre the two groups being studied selected from source populations that are comparable in all respects other than the factor under investigation?NASingle cohort/case series; no controlsDoes the study indicate how many of the people who asked to take part did so, in each of the groups being studied?NARetrospective analysis of single cohort/case series; no controlsIs the likelihood that some eligible subjects might have the outcome at the time of enrolment assessed and taken into account in the analysis?NAAll patients had cancer and hyponatraemia as identified by medical recordsWhat percentage of the individuals or clusters recruited into each treatment arm of the study dropped out before the study was completed?Retrospective analysis; all patients completedIs the comparison made between full participants and those lost to follow up, by exposure status?NANo patients lost to follow upAre the outcomes clearly defined?YesIs the assessment of outcome made blind to exposure status? (if the study is retrospective this may not be applicable)NoRetrospective analysisWhere blinding was not possible, is there some recognition that knowledge of exposure status could have influenced the assessment of outcome?NoIs the method of assessment of exposure is reliable?YesChart reviewIs evidence from other sources used to demonstrate that the method of outcome assessment is valid and reliable?NoIs the exposure level or prognostic factor assessed more than once?NoAre the main potential confounders identified and taken into account in the design and analysis?NoAll patients had different total doses of demeclocycline and different treatment periods; these are listed but not accounted for in the analysisHave confidence intervals been provided?NoConfidence intervals not provided but ranges reported
